Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.50 | 20.80 | 0.24% |
| CAC 40 | 7,804.33 | 12.86 | 0.17% |
| DAX 40 | 23,987.56 | 186.76 | -0.77% |
| Dow JONES (US) | 42,866.87 | 105.11 | 0.25% |
| FTSE 100 | 8,853.08 | 20.80 | 0.24% |
| HKSE | 24,392.47 | 229.60 | 0.95% |
| NASDAQ | 19,714.99 | 123.75 | 0.63% |
| Nikkei 225 | 38,361.68 | 150.17 | 0.39% |
| NZX 50 Index | 12,617.78 | 53.36 | 0.42% |
| S&P 500 | 6,038.81 | 32.93 | 0.55% |
| S&P/ASX 200 | 8,606.80 | 19.60 | 0.23% |
| SSE Composite Index | 3,403.00 | 18.18 | 0.54% |